Thera Neuropharma Awarded Funding from Flemish Agency For Innovation And
Entrepeneurship - Vlaamse Agentschap Innoveren En Ondernemen (VLAIO) 


Berwyn, PA, May 9, 2016/ PRNewswire/ – Thera Neuropharma, Inc., a privately held biopharmaceutical company focused on developing Tangible and Decisive therapeutic interventions for neurodegenerative disorders announced today that it has been awarded a $1,275,000 grant from the Flemish Agency For Innovation And Entrepeneurship - Vlaamse Agentschap Innoveren En Ondernemen (VLAIO).

                                   
                                   
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement
for RXi’s Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics
for Neurodegenerative Diseases, such as ALS (Lou Gehrig’s Disease)


MARLBOROUGH, Mass., May 3, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXi) (NASDAQ: RXII) and privately-held Thera Neuropharma, Inc. (Thera) announced today that they have entered into an exclusive license agreement for RXi's novel and proprietary sd-rxRNA® platform to develop therapeutics for neurodegenerative diseases.